
Free Daily Podcast Summary
by CTI Clinical Trials
A podcast centered on advancements in healthcare and elevating individual’s stories and expertise. Our group of innovative thinkers work to change the lives of chronically and critically ill patients.
The most recent episodes — sign up to get AI-powered summaries of each one.
Alzheimer's disease affects millions of individuals and families, yet many people remain unaware of the critical role early detection can play in improving outcomes. In this episode, host Jeremy Schrand is joined by Andrew Pytlik and Patti Hahn of the Alzheimer's Association to discuss the growing importance of cognitive screening, advances in diagnostic testing, and the steps individuals can take today to support long-term brain health. Together, they explore the realities facing patients, caregivers, and healthcare providers, while sharing why earlier recognition, stronger community support, and continued research are creating new hope for the future of Alzheimer's care.1:00 | Meet the Alzheimer's Association and its mission to support patients, families, and research.3:56 | Why Alzheimer's often develops years before symptoms appear and why early detection matters. 6:47 | Brain health habits that may help reduce risk, including sleep, exercise, and lifestyle choices. 8:42 | Common misconceptions about Alzheimer's and warning signs that go beyond memory loss. 11:27 | New advances in screening, blood-based biomarker testing, and earlier diagnosis. 14:59 | The impact of Alzheimer's on caregivers, families, and the workplace.17:51 | Inside the Walk to End Alzheimer's and how community engagement accelerates research and support. 23:11 | Volunteer, advocacy, and fundraising opportunities that help advance the mission year-round.27:01 | How employer partnerships, including CTI Cares, can strengthen awareness and community impact.29:13 | Looking ahead: the future of Alzheimer's screening, treatment, and hope for patients and families.
Childhood cancer research faces unique challenges, from limited funding opportunities to fewer treatment options compared to adult cancers. In this episode of Moving Medicine Forward, host Jeremy Schrand is joined by Jill Brink, Executive Director of CancerFree KIDS, Dr. Meisam Nami of Cincinnati Children's, and Dr. Ezgi Elmas of CARTx Therapeutics to discuss how early-stage funding is helping researchers pursue bold ideas that could transform pediatric cancer care. Together, they explore the critical role nonprofit organizations play in advancing innovation, the promise of next-generation cell therapies, and how collaboration across research, healthcare, and industry is helping bring new treatment options closer to the children and families who need them most. 00:00 | Introduction to CancerFree KIDS and pediatric cancer research01:37 | Why childhood cancer research needs bold, early-stage funding 04:01 | Bridging the gap between scientific discovery and patient care06:18 | How nonprofit funding helped launch a breakthrough cell therapy innovation 07:06 | Understanding gene-edited and off-the-shelf cancer therapies 10:28 | Closing critical gaps in pediatric cancer research and treatment development 14:54 | The power of collaboration across nonprofits, healthcare, and biotech 18:29 | What gives researchers hope for the future of pediatric cancer care
This week, we're revisiting a previous conversation with Megan Kamm, Senior Vice President of Client Delivery, and Josh Schroeder, Vice President of Site & Field Operations, to discuss how strong planning, site partnerships, and cross-functional collaboration drive successful trial execution. From feasibility and study startup to patient-centered decision-making, biometrics strategy, and global expansion, they share insights into the operational challenges—and opportunities—behind bringing innovative therapies to patients faster. 01:18 Megan Kamm and Josh Schroeder discuss how their expanded leadership roles have created new opportunities to collaborate across functions and support trial delivery. 03:12 The conversation explores the early decisions that shape trial success, from feasibility planning to selecting the right sites and regions. 04:22 Megan explains how site engagement and thoughtful study design help reduce burden and support successful trial execution. 05:28 Josh and Megan share how project teams, CRAs, and other functions work together to keep studies running smoothly. 06:15 The discussion highlights common challenges during study startup and how proactive planning can reduce delays and enrollment risks. 10:23 Josh and Megan provide examples of how strong collaboration helped accelerate enrollment and deliver data more efficiently. 12:32 Megan discusses how biometrics teams contribute from protocol development through data analysis, helping guide study strategy. 13:32 Josh explains how endpoint priorities and statistical planning influence monitoring strategies throughout a trial. 14:43 The conversation turns to leadership, focusing on training, alignment, and consistent decision-making across global teams. 16:02 Megan and Josh reflect on what sets CTI apart, highlighting a culture centered on patients and collaboration. 18:26 The discussion looks at the future of clinical research, including advances in technology, AI, and trial operations. 20:32 Josh shares insights into CTI’s growth in China and the operational considerations that come with expanding into the region.
Childhood cancer research advances through the combined efforts of families, researchers, advocates, and donors. In this episode, Matt Robinson of CancerFree KIDS and Dr. Lindy Miles of Cincinnati Children's discuss how early-stage research funding, clinical trials, and community support help bring new treatments to children with cancer. Matt shares his family's experience navigating leukemia treatment, while Dr. Miles offers insight into the scientific process behind developing the next generation of therapies.00:37 Meet Matt Robinson and Dr. Lindy Miles 01:18 A family's childhood cancer journey and "ringing the bell" 03:04 Why Dr. Miles chose pediatric leukemia research 06:02 How CancerFree KIDS supports families and funds research 07:42 The importance of early-stage research funding 10:26 Connecting families, researchers, donors, and advocates 14:36 Understanding clinical trials and research opportunities 18:40 The challenges of pediatric cancer as a rare disease 20:11 Why cancer research takes time and collaboration 26:24 Ways to support childhood cancer research 28:43 The CancerFree KIDS 100 Mile Challenge 32:50 Final thoughts and call to action
After nearly 40 years caring for transplant patients and more than 25 years in clinical research, Dr. Helio Tedesco has made a unique transition from investigator to CRO medical leader. In this episode of Moving Medicine Forward, Dr. Tedesco reflects on the evolution of transplantation medicine, the challenges patients face before and after transplant, and why clinical research remains essential to improving long-term outcomes. He also shares how his experience conducting more than 25,000 transplants now helps shape more practical, patient centered clinical trials at CTI. 01:17 From Investigator to CTI03:33 The Evolution of Transplant Medicine05:20 Challenges Facing Transplant Patients07:53 A Lifelong Commitment to Research10:07 Designing Better Clinical Trials12:58 25,000+ Transplants Later14:13 What's Next for Transplantation?
In this episode of Moving Medicine Forward, Jeremy Schrand is joined by Luke Devey, Chief Medical Officer at Quell Therapeutics, and Savannah Doliboa, Chief Commercial Officer at CTI, to discuss how engineered regulatory T cell therapies are being developed to “chill, not kill” the immune system. The conversation explores Quell Therapeutics’ approach to Treg cell therapy, the complexity of launching advanced cell therapy trials across Europe, and how strong collaboration helped accelerate study startup for patients with serious autoimmune diseases.00:00 Introduction to Quell Therapeutics and its "Chill, Not Kill" approach to engineered Treg cell therapies 01:13 What engineered regulatory T cells are and how they differ from traditional CAR-T therapies 02:31 Launching a first-in-human basket trial in rheumatoid arthritis and systemic sclerosis with CTI03:05 Why Quell selected the UK, Germany, and Spain for study startup and site activation05:27 Finding the right CRO partner: Why Quell chose CTI Clinical Trial and Consulting Services 07:21 Navigating regulatory pathways, site readiness, and operational complexity in advanced cell therapy trials 10:47 The strategy behind accelerating study startup and overcoming traditional delays12:05 Achieving first-patient-ready status in 113 days, cutting benchmark timelines by 48%13:57 The patient impact: addressing significant unmet needs in rheumatoid arthritis and systemic sclerosis17:00 Key lessons from the trial and building a culture focused on collaboration, innovation, and patient outcomes 20:58 What's next for Quell Therapeutics and the future of engineered Treg cell therapies
Ian Hennessey, Vice President & General Counsel at CTI, joins Moving Medicine Forward to discuss the critical role legal affairs plays in advancing global clinical research. From navigating complex regulations and supporting trial operations to evaluating emerging technologies like AI, Ian shares how legal teams help organizations innovate responsibly while protecting patients and empowering scientific progress00:00 | Career Journey From healthcare law to clinical research. 02:41 | Leadership & Mentorship Building teams through trust, support, and shared problem-solving. 04:11 | Global Research Challenges Navigating regulations across countries while advancing clinical trials. 05:38 | Legal Affairs at CTI How legal operations, contracting, and compliance support research success. 07:31 | Enabling Innovation Balancing business goals, risk, and compliance with a solutions-first mindset. 08:50 | Adapting to Change Managing evolving regulations, technology, and industry expectations. 12:23 | AI and Clinical Research Exploring the opportunities and risks of emerging technologies. 15:41 | Looking Ahead Why the future of clinical research remains so promising. 17:31 | Career Advice Guidance for professionals considering a career in life sciences legal affairs.
What happens behind the scenes to ensure new therapies are safe for patients? In this episode of Moving Medicine Forward, we are joined by John Kane, Vice President of Pharmacovigilance and Safety Services at CTI, to explore the critical role of drug safety throughout the clinical development process. John shares how safety teams collect and evaluate adverse event data, navigate complex global regulations, and help protect patients from clinical trials through post-market surveillance. He also discusses the growing impact of AI in pharmacovigilance, the continued growth of North Carolina's Research Triangle, and the rewarding career opportunities available in clinical research. 01:13 – Finding a Career in Clinical Research John shares how he transitioned from nursing into the clinical research industry. 02:14 – CTI's Growth in Raleigh Why North Carolina's Research Triangle continues to attract biotech companies and research talent. 04:55 – Understanding Pharmacovigilance What pharmacovigilance is and how safety teams collect, evaluate, and report adverse events throughout a drug's lifecycle. 07:33 – Protecting Patients Through Drug Development How CTI safety teams monitor risks, identify safety signals, and communicate important findings to regulators and investigators. 09:55 – Navigating Global Regulations The growing complexity of global safety reporting requirements and regulatory compliance. 11:51 – The Role of AI in Drug Safety How AI may improve data processing, signal detection, and scientific literature review. 13:53 – A COVID-19 Success Story John reflects on supporting a large COVID-19 trial and managing high volumes of safety data. 14:38 – Collaboration at CTI Why teamwork and collaboration are key to successful clinical trials and patient impact. 15:32 – Advice for Future Research Professionals Career opportunities in clinical research and how CTI helps new professionals enter the field.
A podcast centered on advancements in healthcare and elevating individual’s stories and expertise. Our group of innovative thinkers work to change the lives of chronically and critically ill patients.
AI-powered recaps with compact key takeaways, quotes, and insights.
Get key takeaways from Moving Medicine Forward in a 5-minute read.
Stay current on your favorite podcasts without falling behind.
It's a free AI-powered email that summarizes new episodes of Moving Medicine Forward as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by CTI Clinical Trials.
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
Moving Medicine Forward publishes weekly. Our AI generates a summary within hours of each new episode.
Moving Medicine Forward covers topics including Science, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.